| [1] |
中华医学会感染病学分会艾滋病丙型肝炎学组，中国疾病预防控制中心．中国艾滋病诊疗指南(2018版)[J]. 新发传染病电子杂志，2019，4(02):65-84.
|
| [2] |
Zeng H, Chow EP, Zhao Y, et al. Prevention of mother-to-child HIV transmission cascade in China: a systematic review and meta-analysis[J]. Sex Transm Infect, 2016, 92(2):116-123.
|
| [3] |
Meyers K, Qian H, Wu Y, et al. Early Initiation of ARV During Pregnancy to Move towards Virtual Elimination of Mother-to-Child-Transmission of HIV-1 in Yunnan, China[J]. PLoS One, 2015, 10(9):e0138104.
|
| [4] |
GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017[J]. Lancet HIV, 2019, 6(12):e831-e859.
|
| [5] |
Unaids. Global HIV & AIDS statistics—2020 fact sheet[EB/OL]. (2020-05-06)[2020-05-06]．
URL
|
| [6] |
Qiao YC, Xu Y, Jiang DX, et al. Epidemiological analyses of regional and age differences of HIV/AIDS prevalence in China, 2004-2016[J]. Int J Infect Dis, 2019, 81:215-220.
|
| [7] |
姜金茹，周玉博，李宏田，等.2016年中国孕产妇艾滋病病毒感染空间分布特征[J]. 中华医学杂志，2018，98(41):3360-3364.
|
| [8] |
Huang Z, Jin M, Zhou H, et al. The Uptake of Prevention of Mother-to-Child HIV Transmission Programs in China: A Systematic Review and Meta-Analysis[J]. PLoS One, 2015, 10(8):e0135068.
|
| [9] |
Panel on treatment of pregnant women with HIV infection and prevention of perinatal transmission. Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States[EB/OL](2019-12-24)[2020-05-06]．
URL
|
| [10] |
王奇，司珩，马彦民，等．河南省2002-2014年预防艾滋病母婴传播干预工作效果研究[J]. 河南医学研究，2017，26(9):1537-1540.
|
| [11] |
刘冬梅，秦燕，韦丹燕，等．不同孕周高效抗反转录病毒治疗对HIV母婴阻断效果的比较[J]. 中国临床新医学，2016，9(9):770-772.
|
| [12] |
Wang Q, Wang L, Fang L, et al. Timely antiretroviral prophylaxis during pregnancy effectively reduces HIV mother-to-child transmission in eight counties in China: a prospective study during 2004-2011[J]. Sci Rep, 2016, 6(1):34526.
|
| [13] |
Pariente G, Leibson T, Carls A, et al. Pregnancy-Associated Changes in Pharmacokinetics: A Systematic Review[J]. PLoS Med, 2016, 13(11):e1002160.
|
| [14] |
Costantine MM. Physiologic and pharmacokinetic changes in Pregnancy[J]. Front Pharmacol, 2014, 5:65.
|
| [15] |
Stek A, Best BM, Wang J, et al. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women[J]. J Acquir Immune Defic Syndr, 2015, 70(1):33-41.
|
| [16] |
Watts DH, Stek A, Best BM, et al. Raltegravir pharmacokinetics during pregnancy[J]. J Acquir Immune Defic Syndr, 2014, 67(4):375-381.
|
| [17] |
Waitt C, Orrell C, Walimbwa S, et al. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study)[J]. PLoS Med, 2019, 16(9):e1002895.
|
| [18] |
Hodel EM, Marzolini C, Waitt C, et al. Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV[J]. Curr Pharm Des, 2019, 25 (5):556-576.
|
| [19] |
Blonk MI, Colbers APH, Hidalgo-Tenorio C, et al. Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy[J]. Clinical Infectious Diseases, 2015, 61(5):809-816.
|
| [20] |
Bhatt DK, Mehrotra A, Gaedigk A, et al. Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver[J]. Clin Pharmacol Ther, 2019, 105(1):131-141.
|
| [21] |
Neumann E, Mehboob H, Ramírez J, et al. Age-Dependent Hepatic UDP-Glucuronosyltransferase Gene Expression and Activity in Children[J]. Front Pharmacol, 2016, 7:437.
|
| [22] |
Clarke DF, Acosta EP, Rizk ML, et al. Raltegravir pharmacokinetics in neonates following maternal dosing[J]. J Acquir Immune Defic Syndr, 2014, 67(3):310-315.
|
| [23] |
Mulligan N, Best BM, Wang J, et al. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV[J]. Aids, 2018, 32:729-737.
|
| [24] |
Momper JD, Best BM, Wang J, et al. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV[J]. Aids, 2018, 32(6):2507-2516.
|
| [25] |
Rahangdale L, Cates J, Potter J, et al. Integrase inhibitors in late pregnancy and rapid HIV viral load reduction[J]. Am J Obstet Gynecol, 2016, 214(3):385.e381-387.
|
| [26] |
Kintu K, Malaba TR, Nakibuka J, et al. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label，randomised controlled trial[J]. Lancet HIV. 2020, 7(5): e332-e339.
|
| [27] |
Brites C, Nobrega I, Luz E, et al. Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women[J]. HIV Clin Trials, 2018, 19(3):94-100.
|
| [28] |
中华医学会热带病与寄生虫学分会艾滋病学组，中华医学会感染病学分会艾滋病学组．整合酶抑制剂临床应用专家共识[J]. 上海医药，2018，39(23):19-26,59.
|